Kidney health is a growing global concern, with approximately 850 million people affected by kidney diseases worldwide. Among these, chronic kidney disease (CKD) stands out as a major health challenge. Major factors like diabetes and hypertension contribute to its progression, highlighting the urgent need for effective preventive and supportive solutions. Peritoneal dialysis (PD), a life-sustaining therapy for kidney function, often results in complications such as peritoneal fibrosis and inflammation.
Addressing these challenges, Hi-Q Marine Biotech leverages advanced research and Oligo Fucoidan-based dietary ingredients to promote kidney wellness and enhance quality of life. In collaboration with Professor Cheng-Hsien Chen from Taipei Medical University, Hi-Q has recently published two groundbreaking studies:
"Therapeutic potential of Oligo Fucoidan in mitigating peritoneal dialysis-associated fibrosis"
This study shows how Oligo Fucoidan can help reduce inflammation and fibrosis associated with prolonged PD, supporting better peritoneal health and overall wellness.
"Pressure induces peritoneal fibrosis and inflammation through CD44 signaling"
Findings reveal that Oligo Fucoidan helps maintain peritoneal integrity by modulating CD44 pathways, promoting healthy tissue and reducing inflammation.
Hi-Q’s previous research on kidney health
Hi-Q has been actively dedicated to kidney health research for years, with three prior publications highlighting the multifaceted potential of Oligo Fucoidan:
- 2017: Inhibition of renal fibrosis via CD44 signaling.
- 2021: Protective effects of Oligo Fucoidan combined with other compounds in CKD mice.
- 2022: Amelioration of acute kidney injury through immune response modulation.
Innovative ingredients for kidney wellness
Hi-Q’s proprietary Oligo Fucoidan ingredients are offered in two key product lines: OliFuco® Series for advanced kidney care and FucoBalan® Series for comprehensive wellness solutions. By leveraging scientific advancements and sustainable innovation, Hi-Q continues to pave the way for better kidney health outcomes worldwide.
References
Chen et al. Mar. Drugs 2024
Chen et al. Epub. 2024
Chen et al. Sci Rep. 2017
Chen et al. Eur J Pharmacol. 2021
Chen et al. Nutrients. 2022
